NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kulkarni - President of Lab Operations and CSO Conference Call Participants Alex Nowak - Craig-Hallam Capital Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Puneet Souda - SVB Securities Andrew Cooper - Raymond James Mark Massaro - B ...

| --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | August 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

Financial Data and Key Metrics Changes - Revenue increased 3% year-over-year to $125 million [27] - Clinical services revenue increased 4% year-over-year to $106 million [27] - Average revenue per test increased 7% year-over-year to $387 [27] - GAAP gross margin was 35.1%, while adjusted gross margin was 39%, a decline of 450 basis points year-over-year [31] - Adjusted EBITDA loss was $16 million for the quarter, which is a $3 million improvement from Q1 [35] Business Line Data and Key Metrics Changes - Clinical test volume increased 3% sequentially but was down 3% year-over-year [27] - Pharma services bookings were $46 million in Q2, with a backlog of $299 million, up 6% sequentially and 26% year-over-year [28] - Pharma services revenue increased 6% sequentially to $19 million but was down 4% year-over-year [29] - Informatics revenue continues to grow rapidly within pharma services [30] Market Data and Key Metrics Changes - Volume growth continues to be impacted by operational challenges and a market shift from smaller panels to larger offerings [27] - The company is working to upgrade its NGS product offering and improve lab operations [27] Company Strategy and Development Direction - The company is focused on an 18-month performance improvement initiative called Project Catalyst, which encompasses lab optimization, people and capabilities, competitive growth, and insights and analytics [40][42] - The company is pursuing reimbursement for additional cancer types and anticipates filing a second submission for breast cancer in the first half of 2023 [24] - The incoming CEO, Chris Smith, emphasizes the strategic value of combining clinical business with Pharma Services capabilities and Inivata's liquid biopsy technology [54] Management's Comments on Operating Environment and Future Outlook - Management views 2022 as a rebuilding year, focusing on improving product offerings and operational efficiency [36] - The company expects Q3 revenue to be modestly below Q2, with full-year revenue expected to be flat to up modestly year-over-year [37] - Management anticipates improvement in Q4 and plans to reinstate guidance when reporting Q4 earnings in February [38] Other Important Information - The company has made significant leadership changes, including the appointment of Chris Smith as the new CEO [12][15] - The transition to a new lab facility has been completed, which is expected to lead to improvements in service levels and gross margins [33][130] Q&A Session Summary Question: What is impacting clinical testing volumes? - Management indicated that volume decline is primarily due to internal operational service levels and a shift to more comprehensive offerings, rather than solely a COVID-related hangover [68] Question: Can you elaborate on RaDaR's resubmission to MolDX? - The resubmission was prompted by requests for additional information regarding whole exome sequencing data, and management is confident about meeting the criteria for approval [74] Question: What is the status of the pharma services business? - There is a growing backlog, but revenue conversion has been softer due to sample makeup from clinical trials, which the company is actively addressing [85] Question: What is the outlook for NGS contributions? - The company is seeing growth in NGS, but it is not yet at market rates, and they are working on broader panel offerings [86] Question: What are the expectations for profitability exiting 2023? - Management is working towards profitability but is cautious about committing to specific metrics until the new CEO has assessed the business [99]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Financial Officer Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor Relations Shashi Kulkarni - Chief Scientific Officer David Sholehvar - Clinical Division President Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Andrew Coope ...

| --- | --- | --- | --- | --- | --- | |-----------------------|-------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investor Presentation | NeoGenomics | | | | | | April 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy s ...

Financial Performance - Consolidated revenue increased by 9.0% compared to 2020, with Clinical Services revenue up by 5.7% and Pharma Services revenue up by 29.1%[227] - Total net revenue increased by $39.9 million, or 9.0%, from $444.4 million in 2020 to $484.3 million in 2021[258] - Clinical Services revenue rose by $21.8 million, or 5.7%, to $404.2 million in 2021, despite exiting COVID-19 PCR testing[258][259] - Pharma Services revenue increased by $18.0 million, or 29.1%, to $80.2 million in 2021, driven by research studies and informatics[260] - The net loss for 2021 was $8.3 million, compared to a net income of $4.2 million in 2020[323] - Basic net loss per share was $0.07, down from a net income per share of $0.04 in the previous year[323] - Total assets increased to $1.87 billion in 2021, up from $988.3 million in 2020, reflecting a growth of 89.3%[321] - Total liabilities also rose to $761.5 million, compared to $294.0 million in 2020, marking an increase of 158.5%[321] - Stockholders' equity increased to $1.11 billion in 2021, up from $694.3 million in 2020, representing a growth of 60.0%[321] Expenses and Costs - Gross profit margin decreased from 41.8% in 2020 to 38.6% in 2021, primarily due to amortization of acquired technology intangibles[264] - General and administrative expenses surged by $77.6 million, or 53.9%, to $221.3 million in 2021, reflecting acquisition costs and increased personnel[266] - Research and development expenses increased significantly by $13.6 million, or 165.8%, to $21.9 million in 2021, focusing on new test development[268] - Sales and marketing expenses rose by $14.7 million, or 30.8%, to $62.6 million in 2021, attributed to higher commissions and expanded sales team[270] - Cost of revenue increased by 15.0% to $297.3 million in 2021, influenced by higher payroll and amortization costs[263] Cash Flow and Financing - Cash used in operating activities was $26.7 million in 2021, which included $15.7 million of acquisition and integration costs and $53.4 million in depreciation and amortization[281] - Cash used in investing activities increased to $632.4 million in 2021, primarily due to $419.4 million for acquisitions and $133.8 million in marketable securities[283] - Cash provided by financing activities was $725.3 million in 2021, significantly higher than $235.6 million in 2020, driven by $408.1 million from equity offerings and $334.4 million from convertible debt[284] - The company had $316.8 million in cash and cash equivalents and $198.6 million in marketable securities as of December 31, 2021, sufficient to support operational liquidity needs for at least the next 12 months[285] Acquisitions and Investments - Acquired Trapelo and Inivata, adding liquid biopsy platform technology and MRD testing capabilities to the oncology testing portfolio[227] - The acquisition of Inivata Limited was completed on June 18, 2021, with a business enterprise value of $552.8 million and a Purchase Option recorded at fair value of $74.3 million[311] - The acquisition of Trapelo Health on April 7, 2021, involved a total purchase consideration of $64.8 million, including cash of $35.6 million and equity valued at $29.2 million[406] - The estimated goodwill from the Trapelo acquisition is approximately $44.7 million, primarily due to expected synergies and the acquisition of an assembled workforce[409] - The Company recorded a gain of $109.3 million for the year ended December 31, 2021, related to the acquisition of Inivata, including a measurement period adjustment of $17.8 million[415] Operational Developments - Transitioned the majority of testing in Fort Myers to a new headquarters and laboratory facility, enhancing capacity for future growth[227] - Plans to expand test offerings, including advanced NGS tools, and continue global expansion in Europe and Asia[224] - Focus on developing informatics and data-related tools to assist stakeholders in identifying patients for clinical trials[225] - Aims to drive down testing costs through investments in information technology and automation[226] Regulatory and Compliance - The company is committed to providing transparency and choice to patients regarding their data handling and use[241] - The company reported a reserve of $11.2 million in long-term liabilities related to a regulatory matter concerning compliance with federal healthcare laws[316] - The financial statements were audited and presented fairly in all material respects as of December 31, 2021, in accordance with U.S. GAAP[302] Market and Economic Factors - The company has operations in multiple countries, exposing it to foreign currency exchange risks, but does not currently hedge these risks[297] - Inflation has not materially affected the business in the past, but ongoing inflationary pressures could negatively impact future financial results[294] - The company does not expect a significant change in its uncertain tax positions related to Federal and State R&D tax credits in the next 12 months[396]

Company Overview - NeoGenomics' total revenue for FY 2021 was $484 million, with a year-over-year growth of 16%[8] - The company performed 1,086,768 core clinical tests in FY 2021[8] - Clinical services accounted for 83% of FY 2021 revenue, while pharma services/informatics contributed 17%[8] - As of December 31, 2021, the company had signed contracts worth over $265 million in backlog for Pharma Services[9] Market and Growth Drivers - The oncology testing market is estimated to grow at an annual rate of 6% to 8%[12] - The number of cancer survivors is projected to increase by 31.4% to 22.2 million by 2030, driving increased testing[14] - The late-phase oncology pipeline increased 100% from 2008 to 2018, with diagnostic testing being critical as additional drugs gain approval[20] Financial Performance (Q4 2021) - Clinical revenue for Q4 2021 was $104.053 million, a decrease of 2.5% compared to Q4 2020 ($106.738 million)[65] - Pharma revenue for Q4 2021 was $21.679 million, an increase of 12.6% compared to Q4 2020 ($19.259 million)[65] - The company recorded $48 million in new signed contracts for Pharma Services in Q4 2021[42] - Adjusted EBITDA for the year ended December 31, 2021, was a loss of $(4,161) thousand, compared to a profit of $34,842 thousand in 2020[70]

Financial Data and Key Metrics Changes - In Q4 2021, consolidated revenue increased by 7% year-over-year to $126 million, with clinical division revenue up 6% and pharma services revenue up 13% to a record $22 million [29][31] - For the full year 2021, consolidated revenue reached $484 million, representing a 16% year-over-year growth excluding COVID PCR testing revenue [12][28] - Adjusted EBITDA loss was $10 million in Q4, primarily due to significant investments in new assays, with a prior period credit reversal impacting gross margin [36][33] Business Line Data and Key Metrics Changes - Clinical division processed nearly 1.1 million clinical tests in 2021, with average revenue per test increasing by 4% to $383 in Q4 [12][30] - Pharma services revenue grew 29% year-over-year in 2021, with $172 million in new signed contracts and a backlog of $267 million at year-end [19][31] - Informatics business showed rapid growth, unaffected by COVID-19, with new product launches anticipated to accelerate sales [21] Market Data and Key Metrics Changes - The company reported strong demand from biopharma clients, with a global footprint enhancing its competitive position [18] - The new laboratory in Suzhou, China, is expected to be strategically important for competing in global clinical trials [20] Company Strategy and Development Direction - The company aims to strengthen its leadership position in cancer testing through comprehensive test offerings and exceptional service levels [14] - Strategic acquisitions of Inivata and Trapelo are expected to boost growth, with integration progressing well [13][22] - The focus for 2022 includes expanding lab operations staff and enhancing productivity through automation and process improvements [17][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovery from COVID-19 impacts, with expectations for mid-teens revenue growth in the latter half of 2022 [40][54] - The company anticipates a significant outlier year in terms of adjusted EBITDA due to investments in RaDaR and other initiatives [41] - Management highlighted the importance of maintaining strong customer relationships and service levels, reflected in a net promoter score exceeding 60 [15][88] Other Important Information - The company exited Q4 with $515 million in cash and marketable securities, positioning it well for growth initiatives and potential M&A [37] - The appointment of Dr. Shashi Kulkarni as Executive Vice President of R&D and Chief Scientific Officer is expected to enhance research and innovation efforts [26][27] Q&A Session Summary Question: Impact of Omicron on Revenue - Management noted that January saw significant revenue impacts due to Omicron, but recovery was expected in February and March [52][54] Question: Update on Sales Force Expansion - The company is on track to add up to 50 sales reps and 8-10 medical science liaisons to support RaDaR and other NGS assays [61][63] Question: Revenue Guidance and Cancer Diagnoses - Guidance reflects expectations for mid-teens growth in the latter half of the year, with new sales force contributions anticipated [70][78] Question: Contribution from Inivata and Informatics - Long-term growth expectations are over 20% for pharma services and over 25% for informatics, with modest contributions from Inivata [90] Question: Regulatory Updates and Pricing for RaDaR - The company is in the process of self-reporting compliance matters, with pricing for RaDaR expected to align with market standards once reimbursement is established [104][107]